Consistently, 3:1:1 cytokine mRNA triplet conferred better anti-tumor efficacy, compared with the same total dose of IL-12 singlet, IL-12/IL-7 doublet, or IL-12/IFN-α doublet, in syngeneic B16F10 mouse model. The gene discussed is IFNA2; the disease is neoplasm.